NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1200-1210

  Guo, Dongmei ^a   Teng, Qingliang ^a   Ji, Chunyan ^b  

^a Taian Central Hospital   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

NOTCH1; PI3K PTEN AKT mTOR; T ALL; T cell development

Indexed keywords

ANTILEUKEMIC AGENT; GAMMA SECRETASE INHIBITOR; GLUCOCORTICOID; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOTCH RECEPTOR; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITIDE 3 KINASE; PHOSPHATIDYLINOSITIDE 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TENSIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CELL CYCLE ARREST; CELL MATURATION; CELL SURVIVAL; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THYMUS;

ANIMALS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THYMUS GLAND; TOR SERINE-THREONINE KINASES;

EID: 79959611236     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.564696     Document Type: Review

References (156)

1. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225-232.
2. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-661. (Pubitemid 121001701)
3. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-271. (Pubitemid 39336870)
4. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-1210. (Pubitemid 47530629)
5. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007;204:1813-1824. (Pubitemid 47236319)
6. Medyouf H, Gao X, Armstrong F, et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010;115:1175-1184.
7. Godfrey DI, Zlotnik A. Control points in early T-cell development. Immunol Today 1993;14:547-553. (Pubitemid 23316714)
8. Weerkamp F, de Haas EF, Naber BA, et al. Age-related changes in the cellular composition of the thymus in children. J Allergy Clin Immunol 2005;115:834-840. (Pubitemid 40460862)
9. Dik WA, Pike-Overzet K, Weerkamp F, et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005;201: 1715-1723. (Pubitemid 41002890)
10. Eberl G, Littman DR. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of ROR gammat+ cells. Science 2004;305:248-251.
11. von Boehmer H. Selection of the T-cell repertoire: receptorcontrolled checkpoints in T-cell development. Adv Immunol 2004;84:201-238. (Pubitemid 38887682)
12. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-776. (Pubitemid 29291335)
13. Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991;67:687-699. (Pubitemid 121001482)
14. de Celis JF, Barrio R, del Arco A, Garcia-Bellido A. Genetic and molecular characterization of a Notch mutation in its Delta- and Serrate-binding domain in Drosophila. Proc Natl Acad Sci USA 1993;90:4037-4041. (Pubitemid 23134161)
15. Weinmaster G. The ins and outs of notch signalling. Mol Cell Neurosci 1997;9:91-102.
16. Matsuno K, Diederich RJ, Go MJ, Blaumueller CM, Artavanis-Tsakonas S. Deltex acts as a positive regulator of Notch signalling through interactions with the Notch ankyrin repeats. Development 1995;121:2633-2644.
17. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000;26:484-489.
18. Mumm JS, Kopan R. Notch signalling: from the outside in. Dev Biol 2000;228:151-165.
19. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-689. (Pubitemid 44268213)
20. Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007;194:459-474. (Pubitemid 47471215)
21. Jarriault S, Le Bail O, Hirsinger E, et al. Delta-1 activation of notch-1 signalling results in HES-1 transactivation. Mol Cell Biol 1998;18:7423-7431. (Pubitemid 28533061)
22. Kuroda K, Tani S, Tamura K, Minoguchi S, Kurooka H, Honjo T. Delta-induced Notch signalling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem 1999;274:7238-7244.
23. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch [see comments]. Nature 1995;377:355-358.
24. Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L, Hamamori Y. HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 2001;21:6071-6079. (Pubitemid 32737821)
25. Chang D, Valdez P, Ho T, Robey E. MHC recognition in thymic development: distinct, parallel pathways for survival and lineage commitment. J Immunol 2000;165:6710-6715. (Pubitemid 32001133)
26. Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 2000;13:73-84.
27. Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating Notch signaling with thymocyte maturation. Immunity 1998; 9:777-786. (Pubitemid 29024457)
28. Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H. Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. Blood 2006;108:305-310. (Pubitemid 43990643)
29. Pirot P, Grunsven LA, Marine JC, Huylebroeck D, Bellefroid EJ. Direct regulation of the Nrarp gene promoter by the Notch signaling pathway. Biochem Biophys Res Comm 2004;322:526-534. (Pubitemid 39490336)
30. Maillard I, Tu L, Sambandam A, et al. The requirement for Notch signaling at the b-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J Exp Med 2006;203:2239-2245. (Pubitemid 44498358)
31. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 2004;117:515-526. (Pubitemid 38610236)
32. Tanaka S, Tsukada J, Suzuki W, et al. The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity 2006;24:689-701. (Pubitemid 43884897)
33. Minter LM, Turley DM, Das P, et al. Inhibitors of gammasecretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 2005;6:680-688. (Pubitemid 41716741)
34. Amsen D, Antov A, Jankovic D, et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 2007;27:89-99. (Pubitemid 47096801)
35. Fang TC, Yashiro-Ohtani Y, del Bianco C, Knoblock DM, Blacklow SC, Pear WS. Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity 2007;27:100-110. (Pubitemid 47096803)
36. Ordentlich P, Lin A, Shen CP, et al. Notch inhibition of E47 supports the existence of a novel signalling pathway. Mol Cell Biol 1998;18:2230-2239. (Pubitemid 28152671)
37. Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol 2001;29:1041-1052. (Pubitemid 32782638)
38. Washburn T, Schweighoffer E, Gridley T, et al. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 1997;88:833-843. (Pubitemid 27164271)
39. Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J. Modulated expression of Notch1 during thymocyte development. Blood 1996;88:970-976. (Pubitemid 26333321)
40. Anderson G, Pongracz J, Parnell S, Jenkinson EJ. Notch ligand-bearing thymic epithelial cells initiate and sustain Notch signaling in thymocytes independently of T cell receptor signalling. Eur J Immunol 2001;31: 3349-3354. (Pubitemid 33100527)
41. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183: 2283-2291. (Pubitemid 26158919)
42. Göthert JR, Brake RL, Smeets M, Dührsen U, Begley CG, Izon DJ. NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis. Blood 2007;110: 3753-3762. (Pubitemid 350159646)
43. Wang SF, Aoki M, Nakashima Y, et al. Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Blood 2008;111:2878-2886.
44. Kindler T, Cornejo MG, Scholl C, et al. K-RasG12Dinduced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008;112:3373-3382.
45. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004;5:247-253. (Pubitemid 38332121)
46. Radtke F, Wilson A, MacDonald HR. Notch signaling in hematopoiesis and lymphopoiesis: lessons from Drosophila. BioEssays 2005;27:1117-1128. (Pubitemid 43076138)
47. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547-558. (Pubitemid 29262657)
48. Hozumi K, Negishi N, Suzuki D, et al. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol 2004;5: 638-644. (Pubitemid 38811889)
49. Schmitt TM, Zuniga-Pflucker JC. T-cell development, doing it in a dish. Immunol Rev 2006;209:95-102.
50. Rampal R, Li AS, Moloney DJ, et al. Lunatic fringe, manic fringe, and radical fringe recognize similar specificity determinants in O-fucosylated epidermal growth factor-like repeats. J Biol Chem 2005;280:42454-42463. (Pubitemid 43023218)
51. Koch U, Yuan JS, Harper JA, Guidos CJ. Fine-tuning Notch1 activation by endocytosis and glycosylation. Semin Immunol 2003;15:99-106. (Pubitemid 36390167)
52. Nie L, Perry SS, Zhao Y, et al. Regulation of lymphocyte development by cell-type-specific interpretation of Notch signals. Mol Cell Biol 2008;28:2078-2090. (Pubitemid 351342637)
53. Wolfer A, Wilson A, Nemir M, MacDonald HR, Radtke F. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. Immunity 2002;16:869-879. (Pubitemid 34786485)
54. Ciofani M, Schmitt TM, Ciofani A, et al. Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J Immunol 2004;172:5230-5239. (Pubitemid 38542020)
55. Ge C, Stanley P. The O-fucose glycan in the ligand-binding domain of Notch1 regulates embryogenesis and T cell development. Proc Natl Acad Sci USA 2008;105: 1539-1544. (Pubitemid 351346550)
56. Onoyama I, Tsunematsu R, Matsumoto A, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007;204:2875-2888. (Pubitemid 350179557)
57. Kitamoto T, Takahashi K, Takimoto H, et al. Functional redundancy of the Notch gene family during mouse embryogenesis: analysis of Notch gene expression in Notch3-deficient mice. Biochem Biophys Res Comm 2005; 331:1154-1162. (Pubitemid 40692479)
58. Vercauteren SM, Sutherland HJ. Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. Blood 2004;104:2315-2322. (Pubitemid 39331828)
59. Wolfer A, Bakker T, Wilson A, et al. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8 T cell development. Nature 2001;2:235-241. (Pubitemid 33706000)
60. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435-7442. (Pubitemid 41637983)
61. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274. (Pubitemid 46962095)
62. Toulany M, Baumann M, Rodemann HP. Stimulated PI3KAKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 2007;5:863-872. (Pubitemid 47294813)
63. Shelton JG, Steelman LS, Abrams SL, et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005;4:822-830. (Pubitemid 41353836)
64. Fruman DA. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochem Soc Trans 2007;35:177-180. (Pubitemid 46596461)
65. Andrews S, Stevens LR, Hawkins PT. PI3K class IB pathway. Sci STKE 2007;2007(407):cm2.
66. Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. J Immunol 2004;172:6615-6625. (Pubitemid 38669096)
67. Deane JA, Kharas MG, Oak JS, et al. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 2007;109:2894-2902. (Pubitemid 46482086)
68. Oak JS, Deane JA, Kharas MG, et al. Sjogren's syndromelike disease in mice with T cells lacking class 1A phosphoinositide- 3-kinase. Proc Natl Acad Sci USA 2006;103:16882-16887. (Pubitemid 44737347)
69. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-1046.
70. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-1034. (Pubitemid 34856039)
71. Webb LMC, Vigorito E, Wymann MP, Hirsch E, Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005;175: 2783-2787. (Pubitemid 41170493)
72. Swat W, Montgrain V, Doggett TA, et al. Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 2006;107:2415-2422. (Pubitemid 43345562)
73. Hagenbeek TJ, Naspetti M, Malergue F, et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and pre-TCR-mediated signaling. J Exp Med 2004;200: 883-894. (Pubitemid 39362924)
74. Xue L, Chiang L, Kang C, Winoto A. The role of the PI3KAKT kinase pathway in T-cell development beyond the beta checkpoint. Eur J Immunol 2008;38:3200-3207.
75. Zinda MJ, Johnson MA, Paul JD, et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001;7:2475-2479. (Pubitemid 32751652)
76. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. Akt1 and Akt2 are required for ab thymocyte survival and differentiation. Proc Natl Acad Sci USA 2007;104:12105-12110. (Pubitemid 47185637)
77. Jones RG, Parsons M, Bonnard M, et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000;191:1721-1734.
78. Ciofani M, Zuniga-Pflucker JC. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005;6:881-888. (Pubitemid 43090442)
79. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008;7: 458-462. (Pubitemid 351366473)
80. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008;105:7797-802. (Pubitemid 351872718)
81. Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by Notch1. Mol Cell Biol 2000;20:7505-7515.
82. Hinton HJ, Clarke RG, Cantrell DA. Antigen receptor regulation of phosphoinositide-dependent kinase 1 pathways during thymocyte development. FEBS Lett 2006;580:5845-5850. (Pubitemid 44584282)
83. Mao C, Tili EG, Dose M, et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 2007;178:5443-5453. (Pubitemid 46674338)
84. Kelly AP, Finlay DK, Hinton HJ, et al. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J 2007;26:3441-3445.
85. Hinton HJ, Alessi DR, Cantrell DA. The serine kinase phosphoinositide- dependent kinase 1 (PDK1) regulates T cell development. Nat Immunol 2004;5:539-545. (Pubitemid 38660467)
86. Lee SY, Kumano K, Masuda S, et al. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia 2005;19:1841-1843. (Pubitemid 41486167)
87. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006;20:537-539. (Pubitemid 43291764)
88. O'Neil J, Calvo J, McKenna K, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006;107: 781-785. (Pubitemid 43076406)
89. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54. (Pubitemid 38167477)
90. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006;107:2223-2233. (Pubitemid 43345539)
91. Bellavia D, Campese AF, Checquolo S, et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA 2002;99:3788-3793. (Pubitemid 34252184)
92. Felli MP, Vacca A, Calce A, et al. PKC theta mediates pre- TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 2005;24:992-1000. (Pubitemid 40313876)
93. Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004;279:2937-2944. (Pubitemid 38114286)
94. Guo D, Ye J, Dai J, et al. Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk Res 2009;33:678-685.
95. Talora C, Campese AF, Bellavia D, et al. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep 2003;4: 1067-1072. (Pubitemid 37527425)
96. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapa- MYC in (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-4724.
97. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110: 278-286. (Pubitemid 47026845)
98. Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000;19:3337-3348. (Pubitemid 30428211)
99. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006;103:18261-18266. (Pubitemid 44871646)
100. Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006;107:2540-2543. (Pubitemid 43345580)
101. Zhu YM, Zhao WL, Fu JF, et al. NOTCH1 mutations in Tcell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006;12:3043-3049.
102. Mansour MR, Duke V, Foroni L, et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res 2007;13:6964-6969. (Pubitemid 350276876)
103. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657. (Pubitemid 34579158)
104. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2: 489-501. (Pubitemid 37328931)
105. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001;3:304-312. (Pubitemid 32851160)
106. Lin X, Böhle AS, Dohrmann P, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001;386:293-301. (Pubitemid 32702759)
107. Krasilnikov M, Adler V, Fuchs SY, et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999;24: 64-69. (Pubitemid 29070245)
108. Martínez-Lorenzo MJ, Anel A, Monleón I, et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3- kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 2000;32:435-445. (Pubitemid 30101624)
109. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
110. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:39-44.
111. DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3kinase/Akt pathway. Ann Oncol 2004;15:1510-1516. (Pubitemid 39409742)
112. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-183. (Pubitemid 41317589)
113. Huang HP, Shih YW, Chang YC, Hung CN, Wang CJ. Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI3K pathway. J Agric Food Chem 2008;56:9286-9293.
114. Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3- kinase signaling cascade. Blood 2008;112:2463-2473.
115. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-279. (Pubitemid 44301348)
116. Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857-871.
117. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-506.
118. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010;27:255-261.
119. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008;68: 935-944. (Pubitemid 351794158)
120. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009;108:180-194.
121. Chen KF, Yeh PY, Hsu C, et al. Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway. J Biol Chem 2009;284:11121-11133.
122. Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009;113:6172-6181.
123. Silva A, Yunes JA, Cardoso BA, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008;118:3762-3774.
124. Jotta PY, Ganazza MA, Silva A, et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010;24:239-242.
125. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009;114:647-650.
126. Remke M, Pfister S, Kox C, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009;114: 1053-1062.
127. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-1178. (Pubitemid 28494715)
128. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-1568. (Pubitemid 29098491)
129. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-355. (Pubitemid 28357906)
130. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523-534. (Pubitemid 32520864)
131. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619. (Pubitemid 44100518)
132. Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell 2003;3:97-99. (Pubitemid 37443380)
133. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemiainitiating cells. Nature 2006;441:475-482. (Pubitemid 44050144)
134. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003;13:478-483. (Pubitemid 37289398)
135. Maehama T, Dixon JE. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378. (Pubitemid 28268370)
136. Hoemann CD, Beaulieu N, Girard L, Rebai N, Jolicoeur P. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-MYC transgenic mice. Mol Cell Biol 2000;20:3831-3842. (Pubitemid 30314482)
137. Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood 2000;96:1906-1913. (Pubitemid 30661076)
138. Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655-664. (Pubitemid 36050558)
139. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-MYC is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20: 2096-2109. (Pubitemid 44157460)
140. Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-MYC. Mol Cell Biol 2006;26:8022-8031. (Pubitemid 44631001)
141. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789. (Pubitemid 26004411)
142. Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003;278:32227-32235. (Pubitemid 37048415)
143. Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 2002;12:1006-1011. (Pubitemid 34703331)
144. Jin YH, Kim H, Oh M, Ki H, Kim K. Regulation of Notch1 NICD and Hes1 expressions by GSK-3alpha beta. Mol Cells 2009;27:15-19.
145. Calzavara E, Chiaramonte R, Cesana D, Basile A, Sherbet GV, Comi P. Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro. J Cell Biochem 2008;103:1405-1412. (Pubitemid 351490710)
146. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008;118:3660-3670.
147. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006;108:1151-1157. (Pubitemid 44232009)
148. Lones MA, Heerema NA, Le Beau MM, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet 2007;172:1-11. (Pubitemid 44908690)
149. van Grotel M, Meijerink JP, van Wering ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008;22:124-131.
150. Deangelo D, Stone R, Silverman L, et al. A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006;24(18 Suppl.): Abstract 6585.
151. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50-58.
152. Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin in inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70:8097-8107.
153. Chiarini F, Falà F, Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin in as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69:3520-3528.
154. Gu L, Zhou C, Liu H, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res 2010;29:150.
155. Sanda T, Li X, Gutierrez A, et al. Interconnecting molecular pathways in
156. Silva A, Jotta PY, Silveira AB, et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gammasecretase inhibitors. Haematologica 2010;95:674-678.